Statistical Consulting News Today

CU Boulder researcher Eric Vance recently won the W.J. Dixon Award for Excellence in Statistical Consulting, in recognition of his work to help statisticians and data scientists become better communicators.

Toronto, ON (PRWEB) September 01, 2022 -- In clinical research and development, comparison to a control is highly recommended by regulatory agencies for the

Utah State University recently named D. Richard Cutler as vice provost of graduate studies.

“The journey to college is mythical for most Black girls in California. Our nation has a long history of racial trauma and discriminatory behavior toward Black students. The urgency of closing the pay and wealth gap makes Black girls’ path to college particularly alarming due to the role Black women often play in being the primary breadwinner in Black households,” wrote Dr. Colette Harris Mathews, founder/principal DEIB Consultant at Harris Mathews Consulting. | By Charlene Muhammad | Cali...

Hundreds of African American women, professionals from different backgrounds and all corners of the Golden State, came together Jan. 31 to discuss a range of issues important to Black women in California.

Dr. Joni Ricks-Oddie is running for Long Beach's 9th City Council district and is currently the only candidate declared for the race.

Article | April 26, 2021 5 Key Takeaways: Insights On Alternative Designs To The Traditional 3+3 Design In Phase 1 Dose Escalation Studies By Abie Ekangaki and Andreas Schreiner Traditionally, Phase 1 trials commonly utilize 3+3 designs to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Studies have shown, however, that two out of three trials employing a 3+3 design failed in identifying the MTD, and better approaches are needed.1 Dur...

Considerations to Improve Patient Outcomes in Early Drug Development, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, attendees will learn about developing a framework for handling multiple endpoints for the drug’s go-to-market label and determining the potential of adaptive design for optimizing the trial. The featured speakers will discuss key interactions and questions to ask when seeking regulatory input of pivotal study designs. A comprehensive examination of the ro...

Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, attendees will learn about the importance of adopting a suitable dose escalation strategy as well as the benefits and challenges of different dose escalation approaches. The risk of selecting a sub-therapeutic dose as the RP2D is a key limitation of the traditional 3+3 dose-escalation design in Phase 1. TORONT...